Iradimed Co Stock Performance
| IRMD Stock | USD 44.70 0.85 1.94% |
The company retains a Market Volatility (i.e., Beta) of 1.47, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Iradimed will likely underperform. Iradimed right now retains a risk of 2.16%. Please check out Iradimed potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to decide if Iradimed will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Iradimed Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound primary indicators, Iradimed is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return 1.94 | Five Day Return 7.09 | Year To Date Return (5.48) | Ten Year Return 351.52 | All Time Return 351.52 |
Forward Dividend Yield 0.0134 | Payout Ratio 0.5065 | Forward Dividend Rate 0.6 | Dividend Date 2024-01-12 | Ex Dividend Date 2024-05-17 |
1 | IRadimed Issues Q1 2024 Earnings Guidance | 02/08/2024 |
2 | Calculating The Intrinsic Value Of IRadimed Corporation | 02/26/2024 |
3 | Those who invested in IRADIMED three years ago are up 93 | 03/13/2024 |
4 | IRadimed Beats Q2 Earnings and Revenue Estimates - Yahoo Movies Canada | 04/02/2024 |
5 | Pivots Trading Plans and Risk Controls - Stock Traders Daily | 04/12/2024 |
6 | Disposition of 5795 shares by John Glenn of Iradimed subject to Rule 16b-3 | 04/15/2024 |
7 | iRadimed resumed at Roth MKM as a buy as only provider of MRI-compatible IV pumps | 04/22/2024 |
8 | Iradimed Set to Announce Quarterly Earnings on Thursday - MarketBeat | 04/26/2024 |
9 | IRMD Stock Earnings iRadimed Beats EPS, Beats Revenue for Q1 2024 | 05/02/2024 |
| Begin Period Cash Flow | 58 M |
Iradimed |
Iradimed Relative Risk vs. Return Landscape
If you would invest 4,500 in Iradimed Co on February 5, 2024 and sell it today you would lose (30.00) from holding Iradimed Co or give up 0.67% of portfolio value over 90 days. Iradimed Co is currently generating 0.0126% in daily expected returns and assumes 2.1604% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of stocks are less volatile than Iradimed, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Iradimed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Iradimed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Iradimed Co, and traders can use it to determine the average amount a Iradimed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0058
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IRMD |
Estimated Market Risk
| 2.16 actual daily | 19 81% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Iradimed is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Iradimed by adding Iradimed to a well-diversified portfolio.
Iradimed Fundamentals Growth
Iradimed Stock prices reflect investors' perceptions of the future prospects and financial health of Iradimed, and Iradimed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Iradimed Stock performance.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.16 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 522.41 M | ||||
| Shares Outstanding | 12.64 M | ||||
| Price To Earning | 28.70 X | ||||
| Price To Book | 7.30 X | ||||
| Price To Sales | 7.98 X | ||||
| Revenue | 65.56 M | ||||
| Gross Profit | 41.28 M | ||||
| EBITDA | 20.04 M | ||||
| Net Income | 17.19 M | ||||
| Cash And Equivalents | 55.59 M | ||||
| Cash Per Share | 4.42 X | ||||
| Total Debt | 2.04 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.83 X | ||||
| Book Value Per Share | 6.01 X | ||||
| Cash Flow From Operations | 13.47 M | ||||
| Earnings Per Share | 1.35 X | ||||
| Market Capitalization | 565.2 M | ||||
| Total Asset | 92.16 M | ||||
| Retained Earnings | 43.26 M | ||||
| Working Capital | 59.67 M | ||||
| Current Asset | 33.95 M | ||||
| Current Liabilities | 2.89 M | ||||
About Iradimed Performance
To evaluate Iradimed Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Iradimed generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Iradimed Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Iradimed market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Iradimed's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 303.80 | 163.52 | |
| Return On Tangible Assets | 0.19 | 0.17 | |
| Return On Capital Employed | 0.26 | 0.24 | |
| Return On Assets | 0.19 | 0.15 | |
| Return On Equity | 0.24 | 0.20 |
Things to note about Iradimed performance evaluation
Checking the ongoing alerts about Iradimed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Iradimed help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 55.0% of the company shares are owned by institutional investors | |
| Latest headline from investorplace.com: IRMD Stock Earnings iRadimed Beats EPS, Beats Revenue for Q1 2024 |
- Analyzing Iradimed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Iradimed's stock is overvalued or undervalued compared to its peers.
- Examining Iradimed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Iradimed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Iradimed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Iradimed's stock. These opinions can provide insight into Iradimed's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Iradimed Stock analysis
When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Iradimed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.185 | Dividend Share 0.15 | Earnings Share 1.35 | Revenue Per Share 5.363 | Quarterly Revenue Growth 0.137 |
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.